Search research articles
Contact Us
Filters
Showing results (1-10 of 188) with videos related to
Page
of 19
Sort By:
Neurology
|
November 12, 2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance
Richard A Rudick
Cleveland Clinic Journal of Medicine
|
November 30, 2011
Multiple sclerosis, natalizumab, and PML: helping patients decide
Richard A Rudick
Postgraduate Medicine
|
August 1, 1990
Helping patients live with multiple sclerosis. What primary care physicians can do
R A Rudick
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|
January 5, 2002
Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications
R A Rudick
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 15, 2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease
Richard A Rudick
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging
|
July 2, 2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis
Richard A Rudick
Archives of Neurology
|
September 17, 1999
Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
R A Rudick
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|
January 5, 2002
Contemporary immunomodulatory therapy for multiple sclerosis
R A Rudick
Current Opinion in Neurology
|
April 2, 2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs
Megan Hyland, Richard A Rudick
Expert Review of Neurotherapeutics
|
April 28, 2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS
Richard A Rudick, Alfred Sandrock
Page
of 19
Search research articles
Search
Showing results (1-10 of 188) with videos related to
Sort By:
Page
of 19
Neurology
|
November 12, 2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance
Richard A Rudick
Cleveland Clinic Journal of Medicine
|
November 30, 2011
Multiple sclerosis, natalizumab, and PML: helping patients decide
Richard A Rudick
Postgraduate Medicine
|
August 1, 1990
Helping patients live with multiple sclerosis. What primary care physicians can do
R A Rudick
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|
January 5, 2002
Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications
R A Rudick
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
July 15, 2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease
Richard A Rudick
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging
|
July 2, 2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis
Richard A Rudick
Archives of Neurology
|
September 17, 1999
Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
R A Rudick
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
|
January 5, 2002
Contemporary immunomodulatory therapy for multiple sclerosis
R A Rudick
Current Opinion in Neurology
|
April 2, 2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs
Megan Hyland, Richard A Rudick
Expert Review of Neurotherapeutics
|
April 28, 2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS
Richard A Rudick, Alfred Sandrock
Page
of 19